tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Akebia Therapeutics (AKBA) and Brainstorm Cell Therapeutics (BCLI)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Akebia Therapeutics (AKBAResearch Report) and Brainstorm Cell Therapeutics (BCLIResearch Report) with bullish sentiments.

Akebia Therapeutics (AKBA)

In a report released yesterday, Mara Goldstein from Mizuho Securities maintained a Buy rating on Akebia Therapeutics, with a price target of $6.00. The company’s shares closed last Wednesday at $0.83.

According to TipRanks.com, Goldstein is a 4-star analyst with an average return of 6.0% and a 39.3% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Neoleukin Therapeutics.

Akebia Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $7.25.

See today’s best-performing stocks on TipRanks >>

Brainstorm Cell Therapeutics (BCLI)

In a report issued on March 29, Jason McCarthy from Maxim Group maintained a Buy rating on Brainstorm Cell Therapeutics, with a price target of $8.00. The company’s shares closed last Wednesday at $3.36.

According to TipRanks.com, McCarthy has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -26.6% and a 16.1% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Lineage Cell Therapeutics, Monopar Therapeutics Inc, and Stealth Biotherapeutics.

Brainstorm Cell Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $8.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on AKBA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed